/
Other
Locally Advanced or Metastatic NSCLC
18
Pipeline Programs↗
19
Active Trials↗
20
Companies Involved↗
Locally Advanced or Metastatic NSCLC is an emerging landscape with 18 programs across 20 companies. The most active players are Jiangsu Aosaikang Pharmaceutical Co., Ltd., Avistone Biotechnology Co., Ltd., CSPC Megalith Biopharmaceutical Co.,Ltd.. 7 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 13
Phase 28
Phase 37
Approved
No programs
Analysis
Modality Breakdown
88%
Small molecule
15 of 17 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 17 classified programs, each share of the total. Modality classified for 100% of 18 pipeline programs.
Analysis
Trial Status
35
clinical trials
Recruiting12 · 34%
Completed7 · 20%
Unknown status6 · 17%
Active, not recruiting4 · 11%
Not yet recruiting3 · 9%
Terminated2 · 6%
Other1 · 3%
Clinical Trials
Trial Activity
35 trials
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)